Trial · NCT00880334
Adverse events378
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 378
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdomen, pain | Gastrointestinal disorders | Vandetanib and Docetaxel | 1 | 70 | |
| other | Abdomen, pain | Gastrointestinal disorders | Placebo and Docetaxel | 0 | 72 | |
| other | Abdomen, pain | Gastrointestinal disorders | Placebo and Docetaxel-Crossover | 0 | 37 | |
| other | Alkaline phosphatase | Investigations | Vandetanib and Docetaxel | 0 | 70 | |
| other | Alkaline phosphatase | Investigations | Placebo and Docetaxel | 1 | 72 | |
| other | Alkaline phosphatase | Investigations | Placebo and Docetaxel-Crossover | 0 | 37 | |
| other | Alopecia | Skin and subcutaneous tissue disorders | Vandetanib and Docetaxel | 3 | 70 | |
| other | Alopecia | Skin and subcutaneous tissue disorders | Placebo and Docetaxel | 1 | 72 | |
| other | Alopecia | Skin and subcutaneous tissue disorders | Placebo and Docetaxel-Crossover | 0 | 37 | |
| other | Anorexia | Metabolism and nutrition disorders | Vandetanib and Docetaxel | 3 | 70 | |
| other | Anorexia | Metabolism and nutrition disorders | Placebo and Docetaxel | 1 | 72 | |
| other | Anorexia | Metabolism and nutrition disorders | Placebo and Docetaxel-Crossover | 1 | 37 | |
| other | Atrial fibrillation | Cardiac disorders | Vandetanib and Docetaxel | 1 | 70 | |
| other | Atrial fibrillation | Cardiac disorders | Placebo and Docetaxel | 0 | 72 | |
| other | Atrial fibrillation | Cardiac disorders | Placebo and Docetaxel-Crossover | 0 | 37 | |
| other | Atrial flutter | Cardiac disorders | Vandetanib and Docetaxel | 1 | 70 | |
| other | Atrial flutter | Cardiac disorders | Placebo and Docetaxel | 0 | 72 | |
| other | Atrial flutter | Cardiac disorders | Placebo and Docetaxel-Crossover | 0 | 37 | |
| other | Bilirubin | Investigations | Vandetanib and Docetaxel | 1 | 70 | |
| other | Bilirubin | Investigations | Placebo and Docetaxel | 0 | 72 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00880334/events